Andrea Dalbeni

机构：University of Verona, Azienda Ospedaliera Universitaria Integrata Verona · ORCID：0000-0003-0402-4176

发表论文 225 篇 · 总被引 3189 次 · h-index 25

代表论文

Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study (2025 · JHEP Reports · 被引 13)
Glucagon‐Like Peptide‐1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta‐Analysis and Clinical Decision Framework (2025 · Cancer Medicine · 被引 7)
Two‐tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross‐sectional study (2025 · Diabetes Obesity and Metabolism · 被引 5)
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab (2025 · Scientific Reports · 被引 4)
Long-term outcomes of atezolizumab–bevacizumab in unresectable hepatocellular carcinoma: A real-world study (2026 · Hepatology · 被引 3)
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study (2026 · The Lancet Digital Health · 被引 3)